Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 April 2020 | Story Department of Communication and Marketing | Photo Charl Devenish
Farmovs
In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.

The University of the Free State (UFS) is committed to supporting government’s efforts to overcome the COVID-19 pandemic. During this challenging time, dedicated staff members at the UFS continue to provide services as a testimony to their commitment to advance public knowledge of COVID-19 for the greater good of South Africa.

The following is a synopsis of the areas in which the UFS is actively assisting.

Public Health Emergency Solidarity Trial
Clinicians from the Department of Internal Medicine, the Department of Critical Care, and the Division of Virology will be working with FARMOVS to participate in the Public Health Emergency Solidarity Trial initiated by the World Health Organization (WHO). This international randomised trial will evaluate four treatment options (remdesivir, lopinavir/ritonavir, lopinavir/ritonavir plus interferon, chloroquine or hydroxychloroquine) for the treatment of COVID-19. 

The trial is expected to include more than 45 countries worldwide, including a number of South African sites. 

Farmovs

FARMOVS is in a planning process to support all the Bloemfontein hospitals, including Pelonomi, Universitas, 3 Military Hospital, Mediclinic, and Rosepark, in conducting the largest global trial on COVID-19 – the Public Health Emergency Solidarity Trial, under leadership of the WHO.   

Negotiations are ongoing between the UFS and the Department of Health in the Free State for FARMOVS to offer support with the continuation of healthcare to non-COVID-19 patients in an attempt to free up space at Universitas Hospital for isolation of COVID-19 patients. 

In 2019, FARMOVS was pre-qualified by the WHO to support clinical studies aimed at improving access to quality generic medicines across the globe.  FARMOVS also receives feasibility requests for support with the evaluation of existing drugs (repurposing) as well as the development of novel drugs for the treatment of COVID-19 – this is an ongoing process.

Disaster Management Training and Education Centre (DiMTEC)
DiMTEC represents the UFS on the Provincial Joint Operation Centre (PROVJOC). The PROVJOC is a fully equipped, dedicated facility that is proactively established to enable all relevant role players /disciplines to jointly manage all safety and security-related aspects of any planned event or any major incident which has occurred or is imminent – especially in the response and recovery operations phase – at the strategic and/or tactical level, using the Unified Command System. This facility is also linked to all other established safety and security centres.

Research and Innovation
The UFS hosts a SARChI Research Chair in vector-borne and zoonotic diseases, and recently invested in the establishment of a biosafety level-3 facility. Hence, there is expertise on the campus to plan and conduct research on zoonotic and medically significant viruses. In addition, there are research groups focusing on protein expression systems with potential for utilisation in the development of diagnostic assays with application in either diagnosis or surveillance.

Currently, researchers at the UFS have established several projects that will contribute directly towards the COVID-19 outbreak.


News Archive

Mafuma aims at elusive tournament victory with Junior Springboks
2016-06-03

Description: Mafuma Tags: Mafuma

The University of the Free State’s Mosolwa Mafuma
recently scored five tries in the Junior Springboks’
three practice matches against a Golden Lions U20
invitation team, a Maties team, and the
South Western Districts. Photo: SASPA

He has never won a rugby tournament, so Mosolwa Mafuma has only one goal: to win the Junior World Cup as Junior Springbok in England.

Even though the 20-year-old Shimlas wing has achieved success, and it is pleasing to excel individually, he believes it is more satisfying when his team triumphs. According to Mafuma, who could just as well be an athletics star, he wants to help the South African U20 team take a different approach.

He and the prop Kwenzo Blose are players from the University of the Free State who will represent the Junior Springboks from 7 to 25 June 2016 in Manchester. The team will play the first of three group matches on 7 June 2016 against Japan in the Academy Stadium.

New approach for SA U20 team
Mafuma, who was Player of the Tournament in his first Varsity Cup in 2016, says the Junior Springboks are well prepared. “We have the skills, and the structures at the Junior Springboks are different than before. There is not just one game plan like playing with big guys. We want to try new things and have a different approach.”

It is with this team that he wishes to achieve something. “It is one thing to be able to say that you are the Player of a Tournament, but your team did not win. I have not won something at school (with St. Benedict’s Boys College in Johannesburg) or this year with the Shimlas.”

Speedster on athletics track
The speedster is one of only a few rugby players who also have a profile on the IAAF website. His fastest time in the 100 m is 10.37 seconds (a national U17 record) and 20.37 s in the 200 m.

In high school, this first-year Psychology student played rugby during winter and took part in athletics during summer. Only at the end of Grade 11 did he started focusing on rugby. “I was more of an athlete than a rugby player,” he says.

It is no coincidence that the nickname he acquired due to his speed, is Dash. His other nickname, Senkie (derived from the Afrikaans word ‘seuntjie’) he received as a child from his parents because he was such a small child.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept